United States · 
What does Prospect Venture Partners invest in?
Prospect Venture Partners invests most often at Series B and Series A (56% of the rounds on record), in sectors such as Life Sciences and Biomedical.
Prospect Venture Partners highlights
- 01
59 rounds on record
- 02
Mostly Series B and Series A: 56% of its rounds
- 03
Sole investor in 3 rounds, median $11M
- 04
10 exits from the portfolio
What they do
Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biomedical companies.From their own website
- Type
- VC firm
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- Life SciencesBiomedical
- Based in
- Palo Alto, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first59 appearances
- 2014
2 rounds
- Apr
- Mar
- 2013
1 round
- Jul
- 2012
2 rounds
- Jun
- Feb
- 2011
7 rounds
- Nov
- Nov
- Oct
- Oct
- Sept
- Jan
- Jan
- 2010
7 rounds
- Oct
- Oct
- Aug
- Jul
- Jun
- Jan
- Jan
- 2009
9 rounds
- Dec
- Oct
- Sept
- Aug
- Aug
- Jun
- May
- Jan
- Jan
- 2008
4 rounds
- Sept
- May
- Apr
- Feb
- 2007
6 rounds
- Dec
- Jul
- Jun
- Apr
- Apr
- Mar
- 2006
3 rounds
- Sept
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 3 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
3 of 13 we have independently watched raise
insmedportolasentreheartNGMNine pointamiraaveoiduninfinityjazz2nanopanmiravitae
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed10 in all
Kythera BiopharmaceuticalsBought by Allergan$2.1BJun 2015
Portola PharmaceuticalsListed$100MMay 2013
BaxanoBought by TranS1UndisclosedMar 2013
NeomendBought by C. R. Bard$140MOct 2012
Amira PharmaceuticalsBought by Bristol-Myers Squibb$325MJul 2011
AVEO PharmaceuticalsListedUndisclosedMar 2010
Gloucester PharmaceuticalsBought by Celgene$640MDec 2009
VisiogenBought by Abbott Labs$400MSept 2009
Jazz PharmaceuticalsListedUndisclosedMay 2007
An exit counts when it came after the firm's first round in the company. From historical deal records.